For the quarter ending 2026-03-31, OTLC has $393,955,039 in assets. $131,743,498 in debts.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Prepaid & other current assets | - | - | 1,179,972 | 10,594 |
| Cash | 63,614 | 88,857 | 409,000 | 88,022 |
| Restricted cash | 20,000 | 20,000 | 20,000 | 20,000 |
| Accounts receivable | 2,058 | 51,324 | 3,976 | 18,976 |
| Prepaid & other current assets | 1,979,377 | 1,038,071 | - | - |
| Total current assets | 2,065,049 | 1,198,252 | 1,612,948 | 137,592 |
| In process r&d | 1,101,760 | 1,101,760 | 1,101,760 | 1,101,760 |
| Goodwill, net of impairment | 2,788,230 | 2,788,230 | 2,788,230 | 2,788,230 |
| Investment in gmp bio at fair value | 388,000,000 | 388,000,000 | 22,653,225 | 22,653,225 |
| Total assets | 393,955,039 | 393,088,242 | 28,156,163 | 26,680,807 |
| Accounts payable and accrued liabilities | 2,470,889 | 2,571,123 | 2,565,877 | 2,487,234 |
| Accounts payable to related party-Related Party | 348,625 | 348,111 | 347,598 | 347,084 |
| Contingent consideration | 2,625,000 | 2,625,000 | 2,625,000 | 2,625,000 |
| Derivative liability on notes | 440,124 | 350,044 | 670,844 | 278,786 |
| Convertible debt and short-term debt, net of costs-Nonrelated Party | 8,246,199 | 8,225,669 | 10,328,100 | 9,940,174 |
| Convertible debt and short-term debt, net of costs-Related Party | 4,273,152 | 4,023,331 | 3,542,244 | 3,608,634 |
| Total current liabilities | 18,403,989 | 18,143,278 | 20,079,663 | 19,286,912 |
| Convertible debt | - | 1,663,405 | - | - |
| Convertible long-term debt, net of costs | 1,789,509 | - | - | - |
| Deferred income tax liability | 111,550,000 | 111,550,000 | - | - |
| Total liabilities | 131,743,498 | 131,356,683 | 20,079,663 | 19,286,912 |
| Convertible preferred stock, 0.01 par value, 15,000,000 shares authorized 50,900 and 24,388 shares issued and outstanding, respectively | 509 | 244 | - | - |
| Common stock, 0.01 par value 750,000,000 shares authorized 444,197,302 and 442,596,856 issued and outstanding, respectively | 4,441,970 | 4,425,968 | 4,394,463 | 4,082,927 |
| Additional paid-in capital | 49,798,210 | 47,095,219 | 43,765,008 | 42,279,570 |
| Accumulated equity | 209,045,388 | 211,239,164 | -39,108,893 | -38,061,528 |
| Total oncotelic therapeutics, inc. stockholders equity | 263,286,077 | 262,760,595 | 9,050,578 | 8,300,969 |
| Non-controlling interests | -1,074,536 | -1,029,036 | -974,078 | -907,074 |
| Total stockholders equity | 262,211,541 | 261,731,559 | 8,076,500 | 7,393,895 |
| Total liabilities and stockholders equity | 393,955,039 | 393,088,242 | 28,156,163 | 26,680,807 |